Skip to main content
Journal cover image

Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.

Publication ,  Journal Article
Hurwitz, H; Kabbinavar, F
Published in: Oncology
2005

For several decades, 5-fluorouracil (5-FU) with or without leucovorin defined the standard of care for the treatment of metastatic colorectal cancer (CRC). The addition of other chemotherapy regimens to 5-FU has improved survival, but often at the expense of increased toxicity. Recent advances in our understanding of the molecular basis of CRC have led to the production of novel targeted agents, such as bevacizumab (Avastin). Bevacizumab is currently approved for the first-line treatment of metastatic CRC and is currently being tested in combination with standard therapies for a range of indications. Phase II/III trials have demonstrated that the addition of bevacizumab to 5-FU-based first-line chemotherapy improves survival, progression-free survival and response rate compared with chemotherapy alone. Combination therapy does not appear to exacerbate side effects known to be associated with the chemotherapy regimen. The most common side effects attributable to bevacizumab therapy include hypertension, proteinuria and bleeding. Although uncommon, gastrointestinal perforation and arterial thromobembolic events are the most serious side effects reported to date. Bevacizumab is currently being evaluated in combination with oxaliplatin (Eloxatin)-based therapies and preliminary data are encouraging. Ongoing trials of bevacizumab in combination with standard first-line chemotherapy regimens will evaluate bevacizumab's potential in a range of cancer types. .

Duke Scholars

Published In

Oncology

DOI

ISSN

0030-2414

Publication Date

2005

Volume

69 Suppl 3

Start / End Page

17 / 24

Location

Switzerland

Related Subject Headings

  • Treatment Outcome
  • Pyrimidines
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Leucovorin
  • Irinotecan
  • Humans
  • Fluorouracil
  • Deoxycytidine
  • Colorectal Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hurwitz, H., & Kabbinavar, F. (2005). Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology, 69 Suppl 3, 17–24. https://doi.org/10.1159/000088480
Hurwitz, Herbert, and Fairooz Kabbinavar. “Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.Oncology 69 Suppl 3 (2005): 17–24. https://doi.org/10.1159/000088480.
Hurwitz, Herbert, and Fairooz Kabbinavar. “Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.Oncology, vol. 69 Suppl 3, 2005, pp. 17–24. Pubmed, doi:10.1159/000088480.
Journal cover image

Published In

Oncology

DOI

ISSN

0030-2414

Publication Date

2005

Volume

69 Suppl 3

Start / End Page

17 / 24

Location

Switzerland

Related Subject Headings

  • Treatment Outcome
  • Pyrimidines
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Leucovorin
  • Irinotecan
  • Humans
  • Fluorouracil
  • Deoxycytidine
  • Colorectal Neoplasms